The CARVTOP-ICD study is about comparing two medicines, carvedilol and metoprolol succinate, for people with heart failure who have a special device called an Implantable Cardioverter Defibrillator (ICD). This device helps keep the heart's rhythm in check. The study includes 2,000 people at 100 locations in the U.S. Participants will either continue taking metoprolol succinate or switch to carvedilol. Both medicines are beta-blockers, which help the heart work better by slowing it down and reducing blood pressure.
- Duration: The study will last up to 3 years.
- Visits: Regular check-ups are needed, including heart tests and surveys.
- Risk & Benefit: Helps find the best medicine for heart failure, but involves switching medications.
Participants must already be using metoprolol succinate, be willing to switch medicines, and have an ICD for heart failure. The study checks how often the ICD is used, hospital visits, and quality of life. For more details, visit www.carvtop.org.